Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).

Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW.

Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3.

2.

A review of the metabolic effects of controlled-release Phentermine/Topiramate.

Kiortsis DN.

Hormones (Athens). 2013 Oct-Dec;12(4):507-16. Review.

3.

Phentermine/topiramate for the treatment of obesity.

Smith SM, Meyer M, Trinkley KE.

Ann Pharmacother. 2013 Mar;47(3):340-9. Review.

PMID:
23482732
4.

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Bays H.

Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Review.

PMID:
20707765
5.

Long-term effects of weight-reducing drugs in people with hypertension.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.

Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. Review.

PMID:
26934640
6.

Combination phentermine and topiramate extended release in the management of obesity.

Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA.

Expert Opin Pharmacother. 2015 Jun;16(8):1263-74. doi: 10.1517/14656566.2015.1041505. Review.

PMID:
25958964
7.

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S.

JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602. Review. Erratum in: JAMA. 2016 Sep 6;316(9):995.

PMID:
27299618
8.

Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.

Kelly EM, Tungol AA, Wesolowicz LA.

J Manag Care Pharm. 2013 Oct;19(8):642-54. Review.

9.

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Bays HE, Gadde KM.

Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738. Review. Erratum in: Drugs Today (Barc). 2012 Jan;48(1):95.

PMID:
22348915
10.

Phentermine and topiramate extended-release for the obesity: new kids on the block.

Katsi V, Marketou M, Kallistratos MS, Tousoulis D, Makris T, Manolis AJ, Vardas P, Kallikazaros I.

Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):35-41. Review.

PMID:
23565717
11.

Fixed-dose combination of phentermine-topiramate for the treatment of obesity.

Halpern B, Faria AM, Halpern A.

Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13. Review.

PMID:
23656337
12.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Xiong GL, Gadde KM.

Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746. Review.

PMID:
24685974
13.

New obesity agents: lorcaserin and phentermine/topiramate.

Fleming JW, McClendon KS, Riche DM.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):1007-16. doi: 10.1345/aph.1R779. Epub 2013 Jun 25. Review.

PMID:
23800750
14.

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.

Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N.

J Hypertens. 2014 Jun;32(6):1178-88. doi: 10.1097/HJH.0000000000000145. Review.

15.

Phentermine and topiramate for the management of obesity: a review.

Cosentino G, Conrad AO, Uwaifo GI.

Drug Des Devel Ther. 2011 Apr 5;7:267-78. doi: 10.2147/DDDT.S31443. Print 2013. Review.

16.

Topiramate-induced weight loss: a review.

Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S.

Epilepsy Res. 2011 Aug;95(3):189-99. doi: 10.1016/j.eplepsyres.2011.05.014. Epub 2011 Jun 17. Review.

PMID:
21684121
17.

Rimonabant for overweight or obesity.

Curioni C, André C.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006162. Review.

PMID:
17054276
18.

Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.

Garvey WT.

Expert Opin Drug Saf. 2013 Sep;12(5):741-56. doi: 10.1517/14740338.2013.806481. Epub 2013 Jun 6. Review.

19.

New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).

Shyh G, Cheng-Lai A.

Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Review.

PMID:
24304809
20.

Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.

Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC.

Obes Rev. 2013 May;14(5):383-92. doi: 10.1111/obr.12015. Epub 2013 Jan 21. Review.

PMID:
23331711
Items per page

Supplemental Content

Write to the Help Desk